Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

NCT04750824 · clinicaltrials.gov ↗

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous, Non-Small Cell Lung Cancer

Interventions

DRUG: Afatinib
DRUG: other systemic therapy

Sponsor

Boehringer Ingelheim